1 Causal associations between body fat accumulation and COVID-19 severity: A

2 Mendelian randomization study

3

4 Satoshi Yoshiji¹⁻⁴, Daisuke Tanaka¹, Hiroto Minamino^{1,4}, Takaaki Murakami¹, Yoshihito Fujita¹,

5 J. Brent Richards^{2,3,5-8†}, and Nobuya Inagaki^{1†}

6

7 ¹ Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto

8 University, Kyoto, Japan

9 ² Department of Human Genetics, McGill University, Montréal, Québec, Canada

10 ³ Kyoto-McGill International Collaborative Program in Genomic Medicine, Graduate School of

11 Medicine, Kyoto University, Kyoto, Japan

12 ⁴ Japan Society for the Promotion of Science, Tokyo, Japan

13 ⁵ Centre for Clinical Epidemiology, Department of Medicine, Lady Davis Institute, Jewish

14 General Hospital, McGill University, Montréal, Québec, Canada.

15 ⁶ Department of Epidemiology, Biostatistics and Occupational Health, McGill University,

16 Montréal, Québec, Canada.

17 ⁷ Department of Twin Research, King's College London, London, United Kingdom.

18 ⁸ Prime Sciences, Montreal, Quebec, Canada.

19 [†]These authors contributed equally to this study.

20

21 **Short title:** Body fat accumulation and COVID-19 severity

22 **Keywords:** COVID-19, body fat accumulation, body composition, Mendelian randomization

23

24 **Correspondence**

25 J. Brent Richards

26 Professor of Medicine, McGill University, Senior Lecturer, King's College London (Honorary),

27 Pavilion H-413, Jewish General Hospital, 3755 Côte-Ste-Catherine Montréal, Québec, H3T

28 1E2, Canada.

29 Tel: +1-514-340-8222

30 Fax: +1-514-340-7529

31 E-mail: brent.richards@mcgill.ca

32

33 Nobuya Inagaki

34 Professor and Chairman, Department of Diabetes, Endocrinology and Nutrition, Graduate

35 School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507,

36 Japan.

37 Tel: +81-075-751-3560

38 Fax: +81-075-751-4244

39 E-mail: inagaki@kuhp.kyoto-u.ac.jp

40

41 Disclosure summary

42 JBR's institution has received investigator-initiated grant funding from Eli Lilly,

43 GlaxoSmithKline and Biogen for projects unrelated to this research. He is the founder of 5

44 Prime Sciences (www.5primesciences.com), which provides research services for biotech,

45 pharma and venture capital companies for projects unrelated to this research. NI received

46 research funds from Terumo Corp., Drawbridge, Inc., and Asken Inc. NI received speaker

47 honoraria from Kowa Co., Ltd., MSD K.K., Astellas Pharma Inc., Novo Nordisk Pharma Ltd.,

48 Ono Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Takeda

49 Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Sumitomo Dainippon Pharma

50 Co., Ltd., Sanofi K.K., Eli Lilly Japan K.K.; received scholarship grant from Kissei

51 Pharmaceutical Co., Ltd., Sanofi K.K., Daiichi-Sankyo Co., Ltd., Mitsubishi Tanabe Pharma

52 Corp., Takeda Pharmaceutical Co., Ltd., Japan Tobacco Inc., Kyowa Kirin Co., Ltd.,

53 Sumitomo Dainippon Pharma Co., Ltd., Astellas Pharma Inc., MSD K.K., Ono Pharmaceutical

54 Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novo

55 Nordisk Pharma Ltd., Novartis Pharma K.K., and Life Scan Japan K.K. NI is an advisory board

56 member of Novo Nordisk. These agencies did not play any role in study design; the collection,

57 analysis, or interpretation of data; the writing of the report; or the decision to submit this paper

58 for publication. The other authors declare no conflict of interests.

59

60 Abstract

61 **Purpose:** The causal effects of body fat mass and body fat-free mass on coronavirus disease
62 2019 (COVID-19) severity remain unclear. Here, we used Mendelian randomization (MR) to
63 evaluate the causal relationships between body fat-related traits and COVID-19 severity.

64 **Material and Methods:** We identified single nucleotide polymorphisms associated with body
65 mass index (BMI) and direct measures of body fat (i.e., body fat percentage, body fat mass,
66 and body fat-free mass) in 461,460, 454,633, 454,137, and 454,850 individuals of European
67 ancestry from the UK Biobank, respectively. We then performed two-sample MR to ascertain
68 their effects on severe COVID-19 (cases: 4,792; controls: 1,054,664) from the COVID-19 Host
69 Genetics Initiative.

70 **Results:** We found that an increase in BMI, body fat percentage, and body fat mass by one
71 standard deviation were each associated with severe COVID-19 (odds ratio (OR)_{BMI} = 1.49,
72 95%CI: 1.19–1.87, $P = 5.57 \times 10^{-4}$; OR_{body fat percentage} = 1.94, 95%CI: 1.41–2.67, $P = 5.07 \times 10^{-5}$;
73 and OR_{body fat mass} = 1.61, 95%CI: 1.28–2.04, $P = 5.51 \times 10^{-5}$). Further, we evaluated
74 independent causal effects of body fat mass and body fat-free mass using multivariable MR
75 and revealed that only body fat mass was independently associated with severe COVID-19
76 (OR_{body fat mass} = 2.91, 95%CI: 1.71–4.96, $P = 8.85 \times 10^{-5}$ and OR_{body fat-free mass} = 1.02, 95%CI:
77 0.61–1.67, $P = 0.945$).

78 **Conclusions:** This study demonstrates the causal effects of body fat accumulation on
79 COVID-19 severity and indicates that the biological pathways influencing the relationship
80 between COVID-19 and obesity are likely mediated through body fat mass.

81 Introduction

82 Coronavirus disease-19 (COVID-19) has infected hundreds of millions of individuals and
83 caused millions of deaths worldwide (1). The severity of COVID-19 varies considerably among
84 individuals, and identifying modifiable risk factors associated with COVID-19 severity is
85 essential for optimizing public health policies, allocating resources, and assisting clinical
86 decisions.

87 A major risk factor for COVID-19 appears to be obesity. A community-based cohort
88 study involving 6.9 million individuals in England showed a positive association between body
89 mass index (BMI) and COVID-19 severity (2). In that study, BMI was significantly associated
90 with hospital admission, admission to an intensive care unit, and death due to COVID-19, with
91 these findings being replicated in other independent observational studies (3, 4). However,
92 these results do not support causation; in fact, interpreting these observations as a causal
93 relationship relies on untestable and usually implausible assumptions, including the absence
94 of unmeasured confounders and reverse causation (5). Given these limitations inherent to
95 traditional observational epidemiology studies, Mendelian randomization (MR) has emerged
96 as a way to mitigate against such shortcomings through its use of genetic variants as
97 instrumental variables in order to infer a causal relationship between exposures and outcomes
98 (6, 7). Using MR, we can estimate the causal effects of genetically predicted levels of
99 adiposity-related exposures on COVID-19 outcomes, in contrast to typical observational

studies that evaluate only associations. Because genetic alleles are randomly assigned at conception, which is generally well before the onset of the disease, the risk of reverse causation is substantially decreased.

The selection of proxy measures of adiposity plays a vital role in evaluating the association between obesity and COVID-19 outcomes. BMI can be measured easily and is therefore a common measurement of obesity in epidemiological studies. However, the key limitation of BMI is that it is an indirect measure of obesity because it is calculated only with height and weight and does not consider body composition (i.e., body fat mass, body fat-free mass, and their ratio) (8). Therefore, direct measures of body fat accumulation (i.e., body fat percentage and body fat mass) might better elucidate the association of body fat with COVID-19 outcomes. Taking this into consideration, we used a dataset of the UK Biobank, which is a prospective cohort in the UK involving ~500,000 individuals (463,844 of which are of European ancestry) with detailed genetic and phenotypic information. Data from the UK Biobank includes measurements of not only BMI but also body fat mass and body fat-free mass acquired through the bioelectrical impedance analysis and dual-energy X-ray absorptiometry along with the results from the genome-wide association studies (GWAS) for these traits (9). Recent MR studies utilized the results from the UK Biobank to obtain single nucleotide polymorphisms (SNPs) associated with body fat accumulation and showed estimated causal effects of body fat on various traits ranging from cardiovascular diseases to

depression (10-13). In light of these promising findings, body fat mass has emerged as a valuable indicator of the deleterious effects of fat accumulation; however, it remains unclear whether fat mass and fat percentage are causally related to severe outcomes of COVID-19.

In this study, we therefore conducted a two-sample MR to assess whether BMI and direct measures of body compositions (i.e., body fat percentage, body fat mass, and body fat-free mass) are causally associated with severe COVID-19 and COVID-19 hospitalization using data from the UK Biobank and the COVID-19 Host Genetics Initiative.

Methods

Instrumental variables for BMI, body fat percentage, body fat mass, and body fat-free mass

Instrumental variables were defined as independent genome-wide significant SNPs ($P < 5 \times 10^{-8}$) for exposure traits. Independence of SNPs was defined as not in linkage disequilibrium with other SNPs ($r^2 < 0.001$ within a 10,000 kb window). The exposures used in this study were BMI, body fat percentage, body fat mass and body fat-free mass. To select SNPs used as instrumental variables, we obtained the GWAS results of BMI, body fat percentage, body fat mass, and body fat-free mass from individuals with European ancestry in the UK Biobank (**Figure 1**), using the OpenGWAS and MR-Base platform of the MRC Integrative Epidemiology Unit at the University of Bristol (14). The fat mass and fat-free mass

of the UK Biobank participants were evaluated by performing bioelectrical impedance analysis using the Tanita BC418MA body composition analyzer (Tanita, Tokyo, Japan). We restricted the analyses to individuals of European ancestry in order to maximize the statistical power, given that the majority of UK Biobank participants were of European ancestry. To select instrumental variables, SNPs were clumped using PLINK (v1.90) according to a linkage disequilibrium threshold of $r^2 < 0.001$ with a clumping window of 10,000 kb using the 1000G European reference panel (9, 14) in order to select an independent SNP with the lowest P -value in each linkage disequilibrium block. When a selected SNP was not present in the results of the GWAS on COVID-19 severity outcomes, we instead used a proxy SNP that was in linkage disequilibrium with the selected SNP instead, with an r^2 of ≥ 0.8 and minor allele frequency of ≤ 0.3 using 1000G European reference panel as described elsewhere (12). We calculated F -statistics for the exposure traits and a genetic correlation between body fat mass and body fat-free mass using LDAK (v5.1) (15).

Severe COVID-19 and COVID-19 hospitalization outcomes

For proxy outcomes of COVID-19 severity, we adopted the outcomes of the COVID-19 Host Genetics Initiative, which is an international consortium that works collaboratively to share data and ideas, recruit patients, and disseminate scientific findings. The outcomes were severe COVID-19 and COVID-19 hospitalization (16). For definitions of COVID-19 outcomes,

the severe COVID-19 group was defined as individuals whose death was due to COVID-19, those requiring respiratory support, or those requiring hospitalization due to symptoms related to laboratory-confirmed SARS-CoV-2 infection. The COVID-19 hospitalization group was defined as individuals requiring hospitalization due to symptoms associated with laboratory-confirmed SARS-CoV-2 infection. We used the largest GWAS summary statistics of the COVID-19 Host Genetics Initiative for severe COVID-19 and COVID-19 hospitalization outcomes in individuals of European-ancestry, excluding those from the UK Biobank. We restricted the population to those of European ancestry in order to minimize confounding due to population stratification. The datasets corresponding to each outcome were as follows: severe COVID-19 (cases: 4,792; controls: 1,054,664; dataset ID: COVID19_HGI_A2_ALL_eur_leave_ukbb_23andme_20210107) and COVID-19 hospitalization (cases: 14,652; controls: 1,114,836; and dataset ID: COVID19_HGI_B2_ALL_eur_leave_ukbb_23andme_20210622). For the definitions of controls in the GWAS data, ancestry-matched controls were sourced from participating population-based cohorts. Controls included individuals whose status of exposure to SARS-CoV-2 was either negative according to electronic health records/questionnaires or unknown (16).

Mendelian randomization

We performed univariable MR using the inverse-variance weighted method (hereinafter referred to as univariable MR) to evaluate the relationship of BMI, body fat percentage, body fat mass, and body fat-free mass with severe COVID-19 and COVID-19 hospitalization. Univariable MR is a weighted linear regression model in which the effect of genetic variants i ($i = 1 \dots n$) on an outcome $\hat{\beta}_{Y_i}$ is regressed on the effect of the same genetic variant i on the exposure $\hat{\beta}_{X_i}$ weighted by the inverse of the squared standard error ($se(\hat{\beta}_{Y_i})^{-2}$). The estimated total effect (θ) of the exposure on the outcome can be formulated as follows:

$$\hat{\beta}_{Y_i} = \theta \hat{\beta}_{X_i} + \epsilon_i, \quad \epsilon_i \sim \mathcal{N}(0, se(\hat{\beta}_{Y_i})^{-2})$$

The instrumental variable assumptions are: (I) Relevance: genetic variant is associated with the exposure. (II) Independence: genetic variant does not share the unmeasured cause or confounder with the outcome. (III) Exclusion restriction: genetic variant does not influence the outcome except through the exposure (6, 7). These assumptions are illustrated by a canonical diagram in **Figure 2**.

Multivariable MR was performed using the inverse-variance weighted method (hereinafter referred to as multivariable MR). This is an extension of univariable MR, in which the effects of genetic variant i ($i = 1 \dots n$) on the outcome ($\hat{\beta}_{Y_i}$) are regressed on the effect of genetic variant i on two exposures of X_1 (fat mass) and X_2 (fat-free mass). In multivariable MR, genetic variants used as instrumental variables are associated with one or both of the exposures (17).

195 The causal associations were evaluated using odds ratios (ORs), which are
196 expressed according to a standard deviation (SD) increase in genetically predicted BMI
197 (kg/m^2), body fat percentage (%), body fat mass (kg), or body fat-free mass (kg).

198 Results with a $P < 0.0125$ were considered statistically significant ($P = 0.05/4$;
199 Bonferroni-corrected significance threshold according to the number of exposures). We note
200 that such a correction is likely overly conservative, given that the exposures are
201 non-independent. MR analyses were performed using TwoSampleMR (v0.5.6) in R (v4.02).
202 This study is conducted in accordance with the STROBE-MR guideline (6, 7). STROBE-MR
203 checklist is provided in **Supplementary material** (18).

204

205 **Sensitivity analysis**

206 We performed the MR-Egger intercept test, Cochran's Q test, and the MR-PRESSO global
207 test (19, 20) to detect horizontal pleiotropy, which occurs when instrumental variables
208 influence outcomes through pathways independent of the exposure. MR-Egger relaxes the
209 exclusion restriction assumption and is valid under the Instrument Strength Independent of
210 Direct Effect (InSIDE) assumption that associations of the genetic variants with the exposure
211 trait are independent of direct effects of the genetic variants on the outcome. Deviation of the
212 MR-Egger intercept from zero indicates horizontal pleiotropy. The results of Cochran's Q test
213 were used to evaluate the heterogeneity of genetic variants used as instrumental variables.

Results of Cochran's Q test were presented with I^2 index, based on which the heterogeneity of genetic variants was defined categorically with I^2 index as low (I^2 index $\leq 25\%$), moderate (I^2 index 26–50%), and high (I^2 index $> 50\%$). Additionally, we performed the MR-PRESSO global test, which can detect horizontally pleiotropic outlier SNPs. A significant result indicates the presence of pleiotropic outlier SNPs and this method then generates ORs after removing and correcting for these outliers (outlier-corrected ORs). MR-PRESSO can also be used to evaluate the distortion of the causal estimates before and after the removal of pleiotropic outlier SNPs following the MR-PRESSO distortion test. MR-PRESSO requires at least 50% of the genetic variants to be valid instruments with no horizontal pleiotropy and also relies on the InSIDE assumption.

Results with a $P < 0.05$ were considered to indicate the presence of horizontal pleiotropy for the MR-Egger intercept test, Cochran's Q test, MR-PRESSO global test, and MR-PRESSO distortion test. Sensitivity analyses were performed with TwoSampleMR (v.0.5.6) and MR-PRESSO (v1.0).

Ethics statements

The UK Biobank and COVID-19 Host Genetics Initiatives obtained ethics approval from the relevant institutional ethics committees. We used publicly available summary statistics of

GWAS results of UK Biobank and COVID-19 Host Genetics Initiative and did not use individual-level data.

Results

Instrumental variables for exposure traits

The characteristics of the exposure traits (BMI, body fat percentage, body fat mass, and body fat-free mass) are presented in **Table 1**. The mean $\pm$ SD BMI was 27.4 ± 4.8 kg/m², body fat percentage was $31.4 \pm 8.5\%$, body fat mass was 24.9 ± 9.6 kg, and body fat-free mass was 53.2 ± 11.5 kg (**Table 1**). For BMI, body fat percentage, body fat mass, and body fat-free mass, 439, 377, 417, and 530 independent genome-wide significant SNPs were identified as instrumental variables from the GWAS results of the UK Biobank, respectively. *F*-statistics for these exposure traits were 507.6, 496.9, 502.2, and 607.4, respectively. The SNPs used as instrumental variables are presented in **Supplementary Table 1** (18).

Severe COVID-19 outcome

For the severe COVID-19 outcome (**Figure 3**), univariable MR showed that the genetically predicted increase per SD in BMI, body fat percentage, and body fat mass was associated with an increased risk of severe COVID-19 ($OR_{BMI} = 1.49$, 95%CI: 1.19–1.87, $P = 5.57 \times 10^{-4}$; $OR_{fat\ percentage} = 1.94$, 95%CI: 1.41–2.67; $P = 5.07 \times 10^{-5}$, $OR_{body\ fat\ mass} = 1.61$, 95%CI 1.28–2.04,

$P = 5.51 \times 10^{-5}$; and $OR_{\text{body fat-free mass}} = 1.31$, 95%CI: 0.99–1.74, $P = 5.77 \times 10^{-2}$). Further, as instrumental variables for body fat mass and body fat-free mass were not independent from each other ($r^2 = 0.64$ for the genetic correlation of the two traits), we performed multivariable MR to elucidate the independent causal effects of body fat mass and body fat-free mass on the severe COVID-19 outcome, which showed that only body fat mass was independently associated with the severe COVID 19 outcome (body fat mass: $OR_{\text{body fat mass}} = 2.91$, 95%CI: 1.71–4.96, $P = 8.85 \times 10^{-5}$, and $OR_{\text{body fat-free mass}} = 1.02$, 95%CI: 0.61–1.67, $P = 0.945$).

COVID-19 hospitalization outcome

For the COVID-19 hospitalization outcome (**Figure 4**), univariable MR showed that a genetically predicted increase per SD in BMI, body fat percentage, body fat mass, and body fat-free mass was associated with an increased risk of COVID-19 hospitalization ($OR_{\text{BMI}} = 1.31$, 95%CI: 1.19–1.44, $P = 3.46 \times 10^{-8}$; $OR_{\text{fat percentage}} = 1.44$, 95%CI: 1.26–1.66, $P = 1.22 \times 10^{-7}$; $OR_{\text{body fat mass}} = 1.32$, 95%CI: 1.20–1.46, $P = 2.52 \times 10^{-8}$; $OR_{\text{body fat-free mass}} = 1.27$ 95%CI: 1.13–1.42, $P = 4.44 \times 10^{-5}$). In multivariable MR, only body fat mass was independently associated with COVID-19 hospitalization ($OR_{\text{body fat mass}} = 2.38$, 95%CI: 1.56–3.61, $P = 5.29 \times 10^{-5}$; $OR_{\text{body fat-free mass}} = 0.82$, 95%CI: 0.56–1.19, $P = 0.293$), consistent with the findings for severe COVID-19.

270 Sensitivity analysis

271 We performed MR-Egger, Cochran's Q test and MR-PRESSO for sensitivity analysis (**Table**
 272 **2**). In the MR-Egger, the 95%CI results of the MR-Egger intercept (Egger-intercept) contained
 273 the null hypothesis value zero for all exposure-outcome relationships, suggesting no evidence
 274 of horizontal pleiotropy. Heterogeneity estimates of instrumental variables were low according
 275 to the I^2 index (I^2 index were $\leq 25\%$ for all exposure traits). However, MR-PRESSO detected
 276 some pleiotropic outlier SNPs in instrumental variables for BMI, body fat percentage, and
 277 body fat mass with the COVID-19 hospitalization outcome (P -value for global test < 0.05).
 278 Nevertheless, results with MR-PRESSO after removal and correction for these pleiotropic
 279 outlier SNPs were directionally consistent with those from univariable MR, supporting the
 280 robustness of the findings with univariable MR. In addition, the MR-PRESSO distortion test
 281 detected no significant distortion in the causal estimates before and after removal of outlier
 282 pleiotropic SNPs.

283

284 Discussion

285 To the best of our knowledge, this is the first MR study to evaluate the causal association
 286 between directly measured body compositions (i.e., body fat percentage, body fat mass, and
 287 body fat-free mass) with COVID-19 severity outcomes. In this study, we found that an increase
 288 in BMI, body fat percentage, and body fat mass were associated with an increased risk of

severe COVID-19 and COVID-19 hospitalization. We further evaluated the independent causal effects of body fat mass and body fat-free mass on these outcomes and revealed that only body fat mass was independently associated with the outcomes.

During the COVID-19 pandemic, obesity has emerged as a major risk factor for COVID-19 outcomes. Multiple observational studies showed that obese individuals present an increased risk of severe diseases, hospitalization, and death due to COVID-19 (2, 3, 21, 22). However, observational studies are prone to confounding bias and reverse causation and do not estimate the causal effects of exposures on outcomes. To overcome these limitations, several MR studies have been performed to evaluate the causal relationship between obesity-related traits and COVID-19 outcomes. Among anthropometric traits including BMI, waist circumference, hip circumference, and waist-to-hip ratio, BMI showed an association with poor COVID-19 outcomes (23). However, BMI is calculated only from height and weight and does not consider body compositions. Moreover, these anthropometric traits are indirect measures of obesity and might not be accurate proxies for body fat. Therefore, it is necessary to evaluate associations between directly measured fat traits (i.e., body fat mass and body fat percentage) and COVID-19 severity. In this MR study, we adopted these directly measured traits as exposure traits and provided novel findings that indicate the causal association of body fat accumulation with severe COVID-19 outcome.

307 We used multivariable MR since most instrumental variables of adiposity effect both
308 fat mass and fat-free mass, although some variants more strongly and proportionally influence
309 fat mass, whereas others influence fat-free mass more strongly. Therefore, multivariable MR
310 can test the differential causal effects of fat mass and fat-free mass. Using this approach,
311 recent MR studies showed differential associations between body fat mass and body fat-free
312 mass with various disorders (10-13). The present findings extend this knowledge to COVID-19.
313 Results from multivariable MR showed that body fat mass but not body fat-free mass was
314 independently associated with severe COVID-19 and COVID-19 hospitalization. The
315 association between body fat mass and COVID-19 severity was strengthened in multivariable
316 MR relative to findings using univariable MR, whereas the effects of body fat-free mass on
317 COVID-19 severity was markedly attenuated in multivariable MR, thereby illustrating the
318 independent associations between body fat mass and COVID-19 severity.

319 The underlying mechanism of these associations remains to be clarified. Obesity is a
320 metabolic disease characterized by systemic changes in metabolism, including insulin
321 resistance, glucose intolerance, dyslipidemia, changes in adipokines (e.g., increased leptin
322 and decreased adiponectin levels), chronic inflammation, and altered immune response, all of
323 which could collectively increase the risk of COVID-19 severity (4, 24, 25). Moreover, obesity
324 causes respiratory dysfunction, including impaired respiratory physiology, increased airway
325 resistance, impaired gas exchange, low lung volume, and low muscle strength, which can also

increase the risk of COVID-19 severity. Furthermore, the physical characteristics of obese individuals render intubation and laryngoscopy difficult, which could also aggravate outcomes (26). Further studies are needed to explore the pathways linking adiposity to increased risk of COVID-19 severity.

This study has several strengths. We used an MR design, which minimized bias from reverse causation and confounders, thereby enabling us to test for causal effects, provided compliance with MR assumptions. In this MR study, we used the data from the UK Biobank for the exposure traits (F -statistics > 10 for all exposure traits) and COVID-19 Host Genetics Initiative for the outcomes, both of which have large sample sizes, thus increasing the statistical power of the analysis. Furthermore, as proxy measures of body compositions, we not only considered BMI, which is a common indirect measure, but also direct measures, including body fat percentage, body fat mass, and body fat-free mass, and revealed associations of these traits with COVID-19 severity.

However, our study also has important limitations. First, the MR analysis relies on several key assumptions, the violation of which compromises causal inference. To test for possible violations of these assumptions, we performed multiple sensitivity analyses. The MR-Egger intercept test did not detect horizontal pleiotropy. Although SNP heterogeneities were detected when analyzing the outcome in terms of COVID-19 hospitalizations, the removal of outlier SNPs via MR-PRESSO still showed results consistent with those from MR

345 with the inverse-variance method. We believe that these sensitivity analyses demonstrate the
346 robustness and validity of the present findings, however we acknowledge that horizontal
347 pleiotropy is difficult to exclude entirely. Second, regarding exposure traits, we used measures
348 derived from the bioelectrical impedance analysis (i.e., body fat percentage, body fat mass,
349 and body fat-free mass) instead of dual-energy X-ray absorptiometry (DXA)-derived
350 measures to maximize statistical power. Although the UK Biobank collected DXA-derived
351 measures for body fat mass, and body fat-free mass, the sample size was markedly smaller
352 for these measurements ($n = 5,170$). Moreover, although DXA-derived measures are
353 generally more accurate than impedance-derived measures, high correlations between the
354 two were reported for fat mass ($r = 0.96$) and fat-free mass ($r = 0.86$) in the UK Biobank
355 dataset (10). Hence, we believe impedance-derived measures can serve as clinically-relevant
356 exposure traits in the present analysis. Third, we only used summary-level data and did not
357 use individual-level data. Therefore, we could not evaluate the nonlinear relationship between
358 exposures and outcomes. However, it should be noted that MR using summary statistics can
359 still test for the presence of causal effects of exposures on outcomes, even if the
360 exposure-outcome relationship is nonlinear (27). Additionally, a recent prospective cohort
361 study of 6.9 million individuals in the UK suggested that BMI and COVID-19 severity show a
362 linear relationship within a BMI range $\geq 23 \text{ kg/m}^2$ (2). Notably, the BMI of a majority of the
363 individuals in the UK Biobank population included in the present analysis fell within this range

($\geq 23 \text{ kg/m}^2$). Fourth, we restricted our analysis to individuals of European ancestry given that majority of participants in the UK Biobank were of European ancestry. Future studies are warranted to evaluate the generalizability of our findings to other populations.

In summary, the present MR study provides evidence that indicates a causal relationship between body fat accumulation and COVID-19 severity. Because excess fat can be reduced by following an appropriate diet and exercising, it might represent an important modifiable risk factor. Thus, body weight reduction considering direct measurements of body fat (i.e., body fat percentage and body fat mass) can be an effective strategy to reduce the risk of COVID-19 severity.

Acknowledgments

The Richards research group is supported by the Canadian Institutes of Health Research (CIHR: 365825; 409511, 100558, 169303), the McGill Interdisciplinary Initiative in Infection and Immunity (MI4), the Lady Davis Institute of the Jewish General Hospital, the Jewish General Hospital Foundation, the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK, Genome Québec, the Public Health Agency of Canada, McGill University, Cancer Research UK [grant number C18281/A29019] and the Fonds de Recherche Québec Santé (FRQS). JBR is supported by a FRQS Mérite Clinical Research Scholarship. Support from Calcul Québec and Compute Canada is acknowledged. TwinsUK is funded by

the Wellcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. These funding agencies had no role in the design, implementation or interpretation of this study. SY and HM are supported by the Japan Society for the Promotion of the Science.

Data availability

All GWAS summary statistics used in this study are publicly available. All results are included in the present article.

393 References

- 394 1. World Health Organization. COVID-19 clinical management: living guidance.
395 <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1> Accessed on 15
396 Nov, 2021.
- 397 2. Gao M, Piernas C, Astbury NM, Hippisley-Cox, J, O’Rahilly, S, Aveyard, P, Jebb SA.
398 Associations between body-mass index and COVID-19 severity in 6.9 million people in
399 England: a prospective, community-based, cohort study. *Lancet Diabetes Endocrinol.*
400 2021;9(6):350–359.
- 401 3. Recalde M, Pistillo A, Fernandez-Bertolin S, Roel E, Aragon M, Freisling H,
402 Prieto-Alhambra D, Burn E, Duarte-Salles T. Body mass index and risk of COVID-19
403 diagnosis, hospitalisation, and death: a cohort study of 2 524 926 Catalans. *J Clin Endocrinol*
404 *Metab.* 2021;106(12):e5030-e5042.
- 405 4. Recalde M, Roel E, Pistillo A, Sena AG, Prats-Urbe A, Ahmed WU, Alghoul H,
406 Alshammari TM, Alser O, Areia C, Burn E, Casajust P, Dawoud D, DuVall SL, Falconer T,
407 Fernández-Bertolín S, Golozar A, Gong M, Lai LYH, Lane JCE, Lynch KE, Matheny ME,
408 Mehta PP, Morales DR, Natarjan K, Nyberg F, Posada JD, Reich CG, Rijnbeek PR, Schilling
409 LM, Shah K, Shah NH, Subbian V, Zhang L, Zhu H, Ryan P, Prieto-Alhambra D, Kostka K,
410 Duarte-Salles T. Characteristics and outcomes of 627 044 COVID-19 patients living with and

- 411 without obesity in the United States, Spain, and the United Kingdom. *Int J Obes.*
- 412 2021;45(11):2347–2357.
- 413 5. Grimes DA, Schulz KF. Bias and causal associations in observational research.
- 414 *Lancet.* 2002;359(9302):248–252.
- 415 6. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson
- 416 SA, Vanderweele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder
- 417 EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the
- 418 Reporting of Observational Studies in Epidemiology Using Mendelian Randomization. *JAMA.*
- 419 2021;326(16):1614.
- 420 7. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA,
- 421 VanderWeele TJ, Timpson NJ, Higgins JPT, Dimou N, Langenberg C, Loder EW, Golub RM,
- 422 Egger M, Davey Smith G, Richards JB. Strengthening the reporting of observational studies
- 423 in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration.
- 424 *BMJ.* 2021;375:n2233.
- 425 8. Rothman KJ. BMI-related errors in the measurement of obesity. *Int J Obes.*
- 426 2008;32(S3):S56–S59.
- 427 9. Rask-Andersen M, Karlsson T, Ek WE, Johansson Å. Genome-wide association
- 428 study of body fat distribution identifies adiposity loci and sex-specific genetic effects. *Nat*
- 429 *Commun.* 2019;10(1):339.

- 430 10. Tikkanen E, Gustafsson S, Knowles JW, Perez M, Burgess S, Ingelsson E. Body
431 composition and atrial fibrillation: a Mendelian randomization study. *Eur Heart J*.
432 2019;40(16):1277–1282.
- 433 11. Larsson SC, Bäck M, Rees JMB, Mason AM, Burgess S. Body mass index and body
434 composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian
435 randomization study. *Eur Heart J*. 2020;41(2):221–226.
- 436 12. Zeng H, Lin C, Wang S, Zheng Y, Gao X. Genetically predicted body composition in
437 relation to cardiometabolic traits: a Mendelian randomization study. *Eur J Epidemiol*.
438 2021;36(11):1157-1168.
- 439 13. Speed MS, Jepsen OH, Børghlum AD, Speed D, Østergaard SD. Investigating the
440 association between body fat and depression via Mendelian randomization. *Transl Psychiatry*.
441 2019;9(1):184.
- 442 14. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess
443 S, Bowden J, Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM,
444 Relton C, Martin RM, Davey Smith G, Gaunt TR, Haycock PC. The MR-Base platform
445 supports systematic causal inference across the human phenome. *eLife*. 2018;7:e34408.
- 446 15. Speed D, Holmes J, Balding DJ. Evaluating and improving heritability models using
447 summary statistics. *Nat Genet*. 2020;52(4):458-462.

- 448 16. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of
449 COVID-19. *Nature*. 2021;600(7889):472-477.
- 450 17. Zuber V, Colijn JM, Klaver C, Burgess S. Selecting likely causal risk factors from
451 high-throughput experiments using multivariable Mendelian randomization. *Nat Commun*.
452 2020;11(1):29.
- 453 18. Yoshiji S, Tanaka D, Minamino H, Murakami T, Fujita Y, Richards JB, Inagaki N.
454 Supplementary material for “Causal association between body fat accumulation and
455 COVID-19 severity: A Mendelian randomization study”. *Figshare*. Deposited Jan 7, 2022.
456 <https://figshare.com/s/c876361a354038ea988f>.
- 457 19. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
458 instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*.
459 2015;44(2):512–525.
- 460 20. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal
461 pleiotropy in causal relationships inferred from Mendelian randomization between complex
462 traits and diseases. *Nat Genet*. 2018;50(5):693–698.
- 463 21. Hippisley-Cox J, Coupland CA, Mehta N, Keogh RH, Diaz-Ordaz K, Khunti K, Lyons
464 RA, Kee F, Sheikh A, Rahman S, Valabhji J, Harrison EM, Sellen P, Haq N, Semple MG,
465 Johnson PWM, Hayward A, Nguyen-Van-Tam JS. Risk prediction of covid-19 related death

- 466 and hospital admission in adults after covid-19 vaccination: national prospective cohort study.
467 *BMJ*. 2021;374:n2244.
- 468 22. Steenblock C, Schwarz PEH, Ludwig B, Linkermann A, Zimmet P, Kulebyakin K,
469 Tkachuk VA, Markov AG, Lehnert H, de Angelis MH, Rietzsch H, Rodionov RN, Khunti K,
470 Hopkins D, Birkenfeld AL, Boehm B, Holt RIG, Skyler JS, DeVries JH, Renard E, Eckel RH,
471 Alberti KGMM, Geloneze B, Chan JC, Mbanya JC, Onyegbutulem HC, Ramachandran A,
472 Basit A, Hassanein M, Bewick G, Spinass GA, Beuschlein F, Landgraf R, Rubino F, Mingrone
473 G, Bornstein SR. COVID-19 and metabolic disease: mechanisms and clinical management.
474 *Lancet Diabetes Endocrinol*. 2021;9(11):786–798.
- 475 23. Aung N, Khanji MY, Munroe PB, Petersen SE. Causal inference for genetic obesity,
476 cardiometabolic profile and COVID-19 susceptibility: a Mendelian randomization study. *Front*
477 *Genet*. 2020;11:586308.
- 478 24. Gammone MA, D'Orazio N. Review: obesity and COVID-19: a detrimental
479 intersection. *Front Endocrinol (Lausanne)*. 2021;12:652639.
- 480 25. Foulkes AS, Selvaggi C, Shinnick D, Lumish H, Kim E, Cao T, Thaweethai T, Qian J,
481 Lu F, Yan J, Cheng D, He W, Clerkin KJ, Madhavan MV, Meigs JB, Triant VA, Lubitz SA,
482 Gupta A, Bassett IV, Reilly MP. Understanding the link between obesity and severe
483 COVID-19 outcomes: Causal mediation by systemic inflammatory response. *J Clin*
484 *Endocrinol Metab*. 2021;dgab629. <https://doi.org/10.1210/clinem/dgab629>.

- 485 26. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic
486 health in patients with COVID-19. *Nat Rev Endocrinol.* 2020;16(7):341–342.
- 487 27. Burgess S, Davies NM, Thompson SG. Instrumental variable analysis with a
488 nonlinear exposure–outcome relationship. *Epidemiology.* 2014;25(6):877–885.

489 **Table 1.** Dataset descriptions.

Data source	Dataset details	Phenotype	Sample size of each dataset	Mean $\pm$ SD
UK Biobank	<ul style="list-style-type: none"> • GWAS in individuals of European ancestry. • Body fat and body fat-free mass were measured using bioelectrical impedance analysis. 	Body mass index	461,460	27.4 $\pm$ 4.8 kg/m ²
		Body fat percentage	454,633	31.4 $\pm$ 8.5%
		Body fat mass	454,137	24.9 $\pm$ 9.6 kg
		Body fat-free mass	454,850	53.2 $\pm$ 11.5 kg
COVID-19 Host Genetics Initiative	<ul style="list-style-type: none"> • Meta-analysis of GWAS in individuals of European ancestry excluding those from UK biobank 	Severe COVID-19	Cases: 4,792 Controls: 1,054,664	–
		COVID-19 hospitalization	Cases: 14,652 Controls: 1,114,836	–

490

491 **Table 2.** Sensitivity analysis results.

Exposures	Outcomes	Sensitivity analysis methods								
		MR-Egger				Cochran's Q test	MR-PRESSO			
		Egger slope (95% CI)	<i>P</i> -value (Egger slope)	Egger intercept (95% CI)	<i>P</i> -value (Egger intercept)	<i>I</i> ² index	Global test <i>P</i> -value	Outlier-corrected OR (95% CI)	Outlier-corrected <i>P</i> -value	Distortion test <i>P</i> -value
Body mass index	Severe COVID-19	1.24 (0.65–2.37)	0.523	0.004 (-0.008–0.015)	0.542	1.8	0.417	No outlier	—	—
Body fat percentage		1.79 (0.62–5.14)	0.282	0.001 (-0.013–0.016)	0.874	9.7	0.108	No outlier	—	—
Body fat mass		1.63 (0.84–3.15)	0.147	-0.0002 (-0.012–0.012)	0.975	4.0	0.273	No outlier	—	—
Body fat-free mass		0.74 (0.38–1.45)	0.378	0.009 (-0.001–0.018)	0.066	5.0	0.551	No outlier	—	—
Body mass index	COVID-19 hospitalization	1.27 (0.99–1.64)	6.34×10 ⁻²	0.001 (-0.004–0.005)	0.812	19.5	0.001	1.3085 (1.3082–1.3088)	7.09×10 ⁻⁹	0.864
Body fat percentage		1.80 (1.17–2.76)	8.04×10 ⁻³	-0.003 (-0.009–0.003)	0.297	18.4	0.003	1.4498 (1.4493–1.4503)	1.60×10 ⁻⁷	0.810
Body fat mass		1.53 (1.17–2.00)	2.31×10 ⁻³	-0.003 (-0.008–0.002)	0.264	17.3	0.004	1.3351 (1.3348–1.3353)	3.98×10 ⁻³	0.881
Body fat-free mass		1.12 (0.85–1.46)	0.433	0.002 (-0.002–0.006)	0.302	12.3	0.174	No outlier	—	—

Figure legends

Figure 1. Schematic representation of the Mendelian randomization study.

SNPs = single nucleotide polymorphisms.

Figure 2. Canonical diagram illustrating the instrumental variable assumptions made in the Mendelian randomization analyses.

Genetic variant **G** is used as an instrumental variable for exposure **X** (body mass index, body fat percentage, body fat mass, or body fat-free mass) to evaluate the causal effect of **X** on the outcome **Y** (severe COVID-19 or COVID-19 hospitalization). Instrumental variable assumptions include: (I) Relevance: genetic variant **G** is associated with exposure **X**. (II) Independence: genetic variant **G** does not share the unmeasured cause or the confounder with the outcome **Y**. (III) Exclusion restriction: genetic variant **G** does not influence the outcome **Y** except through the exposure **X**.

Red solid arrows represent causal effects; grey solid arrows represent causal effects of the unmeasured cause or confounder that do not violate the instrumental variable assumptions; dashed arrows represent causal effects that are specifically prohibited by the instrumental variable assumptions.

511 **Figure 3.** Univariable and multivariable Mendelian randomization analysis of the severe

512 COVID-19 outcome.

513 MR = Mendelian randomization.

514

515 **Figure 4.** Univariable and multivariable Mendelian randomization analysis for the COVID-19

516 hospitalization outcome.

517 MR = Mendelian randomization.

Figure 1. Schematic representation of the Mendelian randomization study.

Figure 2. Canonical diagram illustrating the instrumental variable assumptions made in the Mendelian randomization analyses.

Figure 3. Severe COVID-19 outcome.

Figure 4. COVID-19 hospitalization outcome.